CD274 and non-small cell lung carcinoma: The deployment of immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) in non-small cell lung cancer (NSCLC) has yielded significant improvements in survival rates among certain patients 8, 10.